Works matching DE "SODIUM-glucose cotransporter 2 inhibitors"

Results: 2351
    1

    Outcomes in New User Cohorts of SGLT2 Inhibitors or GLP-1 Receptor Agonists with Type 2 Diabetes and Chronic Kidney Disease.

    Published in:
    Diabetes Therapy, 2025, v. 16, n. 8, p. 1597, doi. 10.1007/s13300-025-01750-7
    By:
    • Layton, J. Bradley;
    • Ziemiecki, Ryan;
    • Johannes, Catherine B.;
    • Pladevall-Vila, Manel;
    • Khan, Anam M.;
    • Ebert, Natalie;
    • Kovesdy, Csaba P.;
    • Christiansen, Christian Fynbo;
    • García-Sempere, Aníbal;
    • Kanegae, Hiroshi;
    • Coleman, Craig I.;
    • Walsh, Michael;
    • Andersen, Ina Trolle;
    • Rodríguez-Bernal, Clara;
    • Cabaniñas, Celia Robles;
    • Thomsen, Reimar W.;
    • Farjat, Alfredo E.;
    • Gay, Alain;
    • Gee, Patrick;
    • Hurtado, Isabel
    Publication type:
    Article
    2
    3
    4
    5

    Erythrocytosis incidence and thromboembolic risk in heart failure with reduced ejection fraction treated with SGLT2 inhibitors: a nationwide register-based cohort study.

    Published in:
    Cardiovascular Diabetology, 2025, v. 24, n. 1, p. 1, doi. 10.1186/s12933-025-02871-w
    By:
    • Mohamed, Abdullahi Ahmed;
    • Andersen, Camilla Fuchs;
    • Christensen, Daniel Mølager;
    • Riis-Vestergaard, Lise Da;
    • Mohammad, Milan;
    • Elmegaard, Mariam;
    • Binding, Casper;
    • Torp-Pedersen, Christian;
    • Biering-Sørensen, Tor;
    • Hansen, Morten Lock;
    • Køber, Lars;
    • Glenthøj, Andreas;
    • Jensen, Jesper;
    • Andersson, Charlotte;
    • Schou, Morten;
    • Gislason, Gunnar
    Publication type:
    Article
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15

    Evaluating the Complications and Risk of Urosepsis after Flexible Ureteroscopy in a Sodium-Glucose Co-transporter-2 Inhibitor Population with Heart Failure with Reduced Ejection Fraction.

    Published in:
    Maedica - a Journal of Clinical Medicine, 2025, v. 20, n. 2, p. 235, doi. 10.26574/maedica.2025.20.2.235
    By:
    • MUNTEANU, Madalina Andreea;
    • NICOLAE, Camelia;
    • DRAGOMIRISTEANU, George;
    • LUNGU, Anca;
    • ANDREI, Irina;
    • IONITA, Dorin;
    • CACOVEANU, Mihai-Catalin;
    • MUNTEANU, Alice-Elena;
    • NANEA, Tiberiu Ioan
    Publication type:
    Article
    16
    17
    18
    19
    20
    21

    Rationale and Design of Prospective, Multicenter, Double-Arm Clinical Trial to Investigate the Efficacy of Tofogliflozin on Left Ventricular Diastolic Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus (TOP-HFPEF Trial)

    Published in:
    Cardiovascular Drugs & Therapy, 2025, v. 39, n. 1, p. 145, doi. 10.1007/s10557-024-07576-y
    By:
    • Ito, Shin;
    • Nakajima, Yuri;
    • Fukuda, Hiroki;
    • Izumi, Chisato;
    • Nakazawa, Gaku;
    • Yamashita, Hajime;
    • Matsuhisa, Hideo;
    • Inoko, Moriaki;
    • Toyoda, Shigeru;
    • Takiuchi, Shin;
    • Kataoka, Toru;
    • Izumiya, Yasuhiro;
    • Abe, Yukio;
    • Sozu, Takashi;
    • Sakata, Yasushi;
    • Emoto, Masanori;
    • Inoue, Teruo;
    • Kitakaze, Masafumi
    Publication type:
    Article
    22
    23
    24
    25
    26

    Dapagliflozin for Atrial Fibrillation.

    Published in:
    Cardiovascular Drugs & Therapy, 2024, v. 38, n. 1, p. 1, doi. 10.1007/s10557-024-07543-7
    By:
    • Li, Na;
    • Chelu, Mihail G.;
    • Birnbaum, Yochai
    Publication type:
    Article
    27
    28
    29
    30
    31
    32

    Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.

    Published in:
    Cardiovascular Drugs & Therapy, 2023, v. 37, n. 3, p. 561, doi. 10.1007/s10557-022-07319-x
    By:
    • Lee, Sharen;
    • Zhou, Jiandong;
    • Leung, Keith Sai Kit;
    • Wai, Abraham Ka Chung;
    • Jeevaratnam, Kamalan;
    • King, Emma;
    • Liu, Tong;
    • Wong, Wing Tak;
    • Chang, Carlin;
    • Wong, Ian Chi Kei;
    • Cheung, Bernard Man Yung;
    • Tse, Gary;
    • Zhang, Qingpeng
    Publication type:
    Article
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44

    Neuroprotective Effect of SGLT2 Inhibitors.

    Published in:
    Molecules, 2021, v. 26, n. 23, p. 7213, doi. 10.3390/molecules26237213
    By:
    • Pawlos, Agnieszka;
    • Broncel, Marlena;
    • Woźniak, Ewelina;
    • Gorzelak-Pabiś, Paulina
    Publication type:
    Article
    45

    Biocomputational Prediction Approach Targeting FimH by Natural SGLT2 Inhibitors: A Possible Way to Overcome the Uropathogenic Effect of SGLT2 Inhibitor Drugs.

    Published in:
    Molecules, 2021, v. 26, n. 3, p. 582, doi. 10.3390/molecules26030582
    By:
    • Mashraqi, Mutaib M.;
    • Chaturvedi, Navaneet;
    • Alam, Qamre;
    • Alshamrani, Saleh;
    • Bahnass, Mosa M.;
    • Ahmad, Khurshid;
    • Alqosaibi, Amany I.;
    • Alnamshan, Mashael M.;
    • Ahmad, Syed Sayeed;
    • Beg, Mirza Masroor Ali;
    • Mishra, Abha;
    • Shaikh, Sibhghatulla;
    • Rizvi, Syed Mohd Danish;
    • Tutone, Marco;
    • Almerico, Anna Maria
    Publication type:
    Article
    46
    47

    The Off-Target Effects, Electrolyte and Mineral Disorders of SGLT2i.

    Published in:
    Molecules, 2020, v. 25, n. 12, p. 2757, doi. 10.3390/molecules25122757
    By:
    • Cianciolo, Giuseppe;
    • De Pascalis, Antonio;
    • Gasperoni, Lorenzo;
    • Tondolo, Francesco;
    • Zappulo, Fulvia;
    • Capelli, Irene;
    • Cappuccilli, Maria;
    • La Manna, Gaetano;
    • Geronikaki, Athina
    Publication type:
    Article
    48
    49
    50

    The role of SGLT2 inhibitors in heart failure.

    Published in:
    American Journal of Pharmacotherapy & Pharmaceutical Sciences, 2022, p. 1, doi. 10.25259/AJPPS_5_2021
    By:
    • Lusk, Kathleen A.;
    • Benitez, Rebekah M.;
    • Carter, Justin;
    • Diocee, Harneal;
    • Snoga, Jenna L.
    Publication type:
    Article